Don't miss out on up-to-date stock-related news for CRISPR Therapeutics.
Investors can largely thank two news items for the jump. First, CRISPR and MaSTherCell SA announced that they have signed a development and manufacturing agreement related to allogeneic CAR-T therapies. The deal calls for MaSTherCell to handle the development and manufacturing of CRISPR's compound CTX101 in clinical studies aimed at treating a number of diseases.
Second, the company announced that it has been awarded a patent for its CRISPR/Cas9 technology in China. The company believes that this patent covers the company's technology in very broad terms, which should help to protect it from competition down the road.
Given the upbeat news flow, it isn't hard to figure out why the share price was lifted last month.
It's great to see that the company continues to partner with others in an effort to move its pipeline forward. CRISPR has already succeeded at landing industry giants like Vertex Pharmaceuticals and Bayer as partners, so adding MaSTherCell to the list is certainly a positive. The collaboration deal with Vertex is especially exciting since it included a hefty upfront payment, and also required Vertex to make an investment in the company.
On the other hand, CRISPR's products are still highly experimental, so shareholders will have a lot of waiting to do before they learn how these products perform in the clinic. For that reason, potential investors must approach this stock with an ultra long-term mindset if they're interested in getting in.